Mercury Biopharmaceutical Profit Margin

The latest profit margin for 6932.TWO is -49678.05% as of June 2026. That compares with -994.58% in the prior-year period — down 4894.9% year over year. That is below the sector sector average of 13.09%. Investors often review this figure alongside Mercury Biopharmaceutical's historical trend and sector peers before judging valuation or financial health.

Over the past year, 6932.TWO's profit margin moved from -994.58% to -49678.05% — a 4894.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Mercury Biopharmaceutical's valuation or profitability profile.

Against its sector companies, 6932.TWO currently prints -49678.05% for profit margin, while the sector average sits near 13.09%. That is roughly 379654.8% below the sector mean. Large gaps often invite a closer look at Mercury Biopharmaceutical's growth, margins, and balance sheet.

Profit Margin shows how effectively Mercury Biopharmaceutical converts resources into returns. At -49678.05%, 6932.TWO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -994.58% in the prior-year period — down 4894.9% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting 6932.TWO's profit margin (-49678.05%), review year-over-year change from -994.58%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.